The FDA has smacked Fresenius Kabi with a warning letter for selling adulterated devices that fail to conform to current good manufacturing practice (cGMP) requirements, following an inspection of the devicemaker’s Waltham, Mass., facility from June 26 to Aug. 2.
Source: Drug Industry Daily